Guest Editors should submit the proposal for a Thematic Issue in an area of considerable current interest to Bentham Science for approval. The proposal should contain the following information:
Tentative title of the Special Issue
One page proposal containing information about the importance of the specific area and the proposed date of submission of the articles
Sub topics of the Thematic Issue (typically 8 to 10 articles)
List of potential contributors (who should all be eminent in the field) along with their affiliations.
Tentative time schedule
In case there are more than one Guest Editors in a special issue, one Guest Editor will serve as the corresponding Editor.
The Guest Editor nominates authors to Bentham, and once they have been approved, invites them to submit papers for the special thematic issue which are of high quality in terms of science and presentation.
Papers submitted for the special or thematic issues are evaluated on the same strict criteria as regular contributed submissions. Each paper must be independently assessed by at least 2 (preferably 3) eminent experts in the field. Evidence for ;
(a) the review process (including names, designations and email addresses of the referees)
(b) evidence for the appropriate modification of the papers as suggested by the referees, and
(c) final acceptance by ALL the referees of the modified manuscripts should be provided to the publisher.
Guest editors take the initial decisions on the acceptance /rejection / revision and resubmission of manuscripts and relay the decision to the editorial office. In selected cases, the papers may be reviewed independently by Bentham and the publisher retains the right to accept or reject the manuscripts. Papers will only be published if they clearly merit publication on the basis of their originality and overall importance of results. Final editorial decisions on all Special/Thematic Issue submissions are generally taken by the Editors-in-Chief of the journal , but are subject to final approval by Bentham Science.
The contributors should be eminent researchers able to give a current overview of the latest developments in the field.
A Guest Editor/Co-Guest Editor may be an author or a co-author in only one manuscript. The guest Editor is also expected to write the Introduction to the issue.
It is recommended that only eminent contributing authors are selected from different regions.
An invitation to submit a paper to a special or thematic issue does not imply guaranteed acceptance for publication. Some submissions may be rejected.
It is a condition of publication that manuscripts submitted to Bentham should not have been published and should not be simultaneously submitted or published elsewhere, and should conform to the ethical guide lines (see https://benthamscience.com/publishing-ethics-main.php).
Guest Editors are required to convey the complete table of contents and the outline of the issue as well as the names and designations of contributing authors before the proposal is tentatively accepted (final acceptance being dependent on the review process). Guest Editors should inform the authors of the proposed time schedule for the Special Thematic Issue and if articles are not submitted in time to the Publisher than they may be eliminated.
Peer Review of Special/Thematic Issue Papers
Our editorial policy requires a minimum of two single-blind reviews for submitted articles.
Selection Criteria: A reviewer must hold a PhD degree and should normally have an h-index above 10.
Reviewers need to be approved by the Publisher prior to sending the articles for review by the Guest Editor.
Peer review of special/thematic issue papers should be conducted by eminent reviewers who are completely independent.
Reviewers cannot be selected from the contributing authors or from among the Guest Editors.
Final editorial decisions on all Special/Thematic Issue submissions will be decided by the Editors-in-Chief.
Bentham Science may carry out independent peer review and reserves the right to reject articles on the basis of such peer review.
When the referee reports have been received, the Guest Editors will be asked to make an initial decision, and where necessary, the paper will be sent back to the authors for revision. Once the Guest Editors have recommended to accept or reject a paper, the final decision will rest with the Editor‐in‐Chief. The editorial office will inform authors of the final status of the paper.
Once the papers have been accepted by the Editor, they are then transmitted to the publisher’s production department. Proofs will be available online for the authors to review and approve before Online publication.
Biopharma Research Leader, Organic and Medical Chemist, Registered US Patent Agent
Dr. Gregory received his bachelor’s and PhD degrees in chemistry from the University of Virginia and worked on the synthesis of complex indole alkaloids. In 1988, he joined Nova Pharmaceuticals Inc. He became the Vice President of Chemistry in 1997.
In 2002, as Vice-President, he joined Artesian Therapeutics in Gaithersburg and designed and patented an IND candidate in a year.
In 2005, he joined MGI PHARMA, as head of the medicinal chemistry. In 2007, he became the Senior Director of Intellectual Property, and in 2008, he worked as senior member of IP group
"GALLY" International Biomedical Research Consulting LLC
Dr. Gjumrakch Aliev, MD, PhD, President “GALLY” International Biomedical Research Institute Inc., San Antonio, Texas, USA. He also hold appointment with the University of Atlanta, as a Professor and as a Leading Scientist , Institute of Physiologically Active Compounds. Russian Academy of Sciences.
He received his MD in 1982, from the Baku Medical University (former USSR) with cum laude. Then he accomplished his PhD in Cardiovascular Diseases from the prestigious Russian Academy of the Medical Sciences, Moscow, Russia in 1988 with cum laude. He authored and coauthored more than 500 publications in the fields of neurodegenerative diseases research (Alzheimer disease), as well as cardio- and cerebrovascular disease, cancer, and electron microscopy.
University of Genova
MSc and MD, fellow of the Provincial Medical and Odontological Register (Genova), of the Italian Society of Experimental Biology and of the Solidarity, Projects and Resources for Africa University Board. He worked at the G.Gaslini Pediatric Hospital of Genova carrying out research on neuroblastoma; at present he deals with ecotoxicology, toxicology, and natural extract activity on cultured cells at the University of Genova (Department of Earth, Environment and Life Sciences). He participated in national and international research projects and working groups, is Associate Editor, Editorial Board member and reviewer for international scientific journals, Guest Editor for special issues of journals and books, and author of 152 publications, including 9 teaching books.
Hungarian Academy of Sciences, Institute of Experimental Medicine
Dr. Zelena is a medical doctor (MD) and obtained a doctorate (PhD) in Neuroscience from the Semmelweis University, Budapest, Hungary. She has more than 20 years of experience in the research for new treatment option aimed to treat CNS and neurological disorders. Currently Dr. Zelena is a Senior Scientist of the Hungarian Academy of Sciences, Institute of Experimental Medicine. She is a neuroendocrinologist, and behavioral neuroscientist. Dr. Zelena is also an adjunct faculty member at University of Pécs, Hungary, where she teaches Physiology to medical students. She published more than 95 articles and 14 book chapters.
Institute of Physiologically Active Compounds Russian Academy of Sciences (IPAC RAS)
Sergey Bachurin received the Ph.D. degree in 1980. Since 1981 he works in the Institute of Physiologically Active Compounds Russian Academy of Sciences (RAS). Since 2006 he is a Director of the Institute. In 2003 he was elected as a member of RAS. His research activity related to the discovery of novel agents for neurodegenerative diseases treatment. Bachurin was invited scholar in University of California, San Francisco and in Tufts University, Boston. He is Russian national representative in IUPAC and Council member of European Federation of Medicinal Chemistry. He is the author of more than 200 and about 40 patents.
Dr. Neumeyer received his BS in Chemistry from Columbia University and PhD in Medicinal Chemistry from the University of Wisconsin, Madison, WI. He joined the faculty of Northeastern University as Professor of Medicinal Chemistry and was appointed Matthews Distinguished Professor. Dr. Neumeyer was a cofounder of Research Biochemicals, Inc. Dr. Neumeyer has had a long career in medicinal chemistry as evidenced in more than 400 scientific publications. He is currently the director of the Medicinal Chemistry Laboratory at McLean Hospital, Harvard Medical School. Dr. Neumeyer was inducted into the American Chemical Society’s Division of Medicinal Chemistry Hall of Fame in 2008.
Dr. Sadayuki Hashioka is an associate professor of Department of Psychiatry, Shimane University, Izumo, Japan. He received his MD in 1998 from the Faculty of Medicine, University of Miyazaki, Japan. After four years of clinical work as a psychiatrist, he received his PhD in 2006 from the Department of Neuropsychiatry, Kyushu University, Fukuoka, Japan.He subsequently obtained five-year training as a postdoctoral fellow under Drs. Edith and Patrick McGeer at the Kinsmen Laboratory of Neurological Research, University of British Columbia, Vancouver, Canada. Since 2012 he has been at his present post
Zhujiang Hospital of Southern Medical University
Prof. D.Q. Wang is Vice-Head at the Department of Neurology, The Third Affiliated Hospital of Sun Yat-Sen University. He obtained his Ph. D from National University of Singapore and he is Postdoctoral Fellow at Stanford University and NHMRC from Australia. He is regular a member of Asia Pacific Society for Neurochemistry, NSFC of China Grant and Committee Member of Chinese Parkinson‘s Disease & Movement Disorders Society, “Frontiers in Cellular Neuroscience”. He was awarded as Young Investigator in 2010 from Ministry of Education. He obtained 26 National Grants and has published 45 SCI papers.
Camilo José Cela University
Dr. Ramón Cacabelos is Professor of Genomic Medicine at Camilo José Cela University, Madrid, and President of the EuroEspes Biomedical Research Center, Corunna, Spain. He received his M.D. from Oviedo University, Ph.D. from Santiago University, and D.M.Sci. (Psychiatry) from Osaka University Medical School, Japan. After a decade at the Department of Psychiatry in Osaka, he returned to Spain and focused his research activity on the genomics and pharmacogenomics of neurodegenerative disorders. He has published over 600 papers and 24 books, and is Editor-in-Chief of the first World Guide for Drug Use and Pharmacogenomics and President of the World Association of Genomic Medicine.
University of Minnesota Medical School
M. Fatemi received his PhD in Electrical Engineering from Purdue University. Currently, he is a Professor of Biomedical Engineering at the Mayo Clinic College of Medicine, and a member of Mayo Clinic Cancer Center, Cancer Imaging Program, and the Center for Translational Science Activities. In addition, he is a faculty member of the Biomedical Informatics and Computational Biology graduate program at the University of Minnesota Rochester. His current research areas include ultrasonic methods for tissue viscoelasticity and nonlinear elasticity estimation for applications in cancer imaging and bladder function evaluation. He is an elected Fellow of IEEE, AIMBE, ASA, and AIUM. He is the recipient of the IEEE-UFFC Distinguished Lecturer award for 2016-2017.
Frontiers Section Editor
Shemyakin & Ovchinnikov Institute
of Bioorganic Chemistry Russian
Academy of Sciences (IBCH RAS)
Yuri N. Utkin received his PhD in Bioorganic Chemistry from the Shemyakin Institute of Bioorganic Chemistry of the Academy of Sciences of the USSR. After earning the PhD degree he continued his career at the same Institute (now the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS), receiving a DSc degree in 1996 and being promoted to Professor in 2006. Prof. Utkin is the head of the laboratory of molecular toxinology. He has published more than 150 scientific publications in peer reviewed journals. Professor Utkin is a member of the European Society for Neurochemistry, the International Society on Toxinology, and the American Society for Biochemistry and Molecular Biology.
Editorial Board Members
University of Santiago de Compostela
Associate Professor University of Santiago de Compostela, Faculty of Veterinary, Lugo. Degree in Pharmacy, University of Santiago de Compostela. PhD in Pharmacy, Neurochemistry, University of Barcelona (1998): neurotoxicity of organic pollutants. Postdoctoral stay at the Center for Neural Science, New York University. Supervisor: Dan H. Sanes. Study of synaptic plasticity in the auditory system (1998-2000). Associate Professor, Faculty of Medicine, University of Castilla-La Mancha (2000-2004). 2004-Present: Study of marine toxins in neuronal systems, Universidade de Santiago de Compostela.
University of Campania "Luigi Vanvitelli"
Dr. Gentile is a recognized expert in the transglutaminase research area and has a strong background in the molecular biology and biochemical aspects of the transglutaminase (TG) enzymes expression, activity and function. His work has been focused to the tTG (TG2) characterization in normal and pathological cellular events (cell growth and differentiation, adhesion, apoptosis, neurodegeneration) by biochemical and molecular biology studies. Currently dr. Gentile is associate professor at the University of Campania “Luigi Vanvitelli” .
Dr. Rakesh Kumar Tiwari is currently an Assistant Professor of Biopharmaceutical and Biomedical Sciences. He joined CUSP in September 2013. He received his Ph.D. (2006) in Organic Chemistry from Dr. B.R. Ambedker Center for Biomedical Research, University of Delhi. In 2007, Dr. Tiwari’s strong interest to conduct research in the area of application of chemistry in biology led him to pursue his postdoctoral research at University of Rhode Island. His postdoctoral work resulted in the synthesis of several peptide as neuroprotective agents, nanomaterials, kinase inhibitors as anticancer compounds, and many cell-penetrating peptide.
University of Rome Tor Vergata
Dr. Beatrice Macchi is Assistant Professor in the Pharmacology Section of Department of Systems Medicine at University of Rome Tor Vergata, Italy. She is also Principal Investigator of the laboratory of molecular antiviral research in the Department of System Medicine, at University of Rome Tor Vergata. Her skills and expertise mainly lie in the subject areas of PCR, Cell Culture, Cancer Biology, Flow Cytometry, Proteins, Biotechnology, Infection, Apoptosis, Immunology of Infectious Diseases, HIV, Cancer Research, etc. Dr. Macchi, as an author/co-author, has published more than 90 articles in various journals, having over 1,200 total citations.
University of Milan
Dr. Bottai has obtained Ph.D. in Neuroscience from the University of Pisa, Italy and McGill University, Montreal, Quebec, Canada. He is presently working as an Assistant Professor in Pharmacology, Department of Science Health University of Milan. He is Ordinary member of the Italian Society of Pharmacology. He is in Collaboration with International Scientific Journals such as Reviewer of The Lancet, Journal of Neurochemistry, Associated Editor: Frontiers in Stem Cells Treatments and Associated Editor: Frontiers in Cell and Developmental Biology. He has contributed more than 30 publications, having citations around 946.
University of Naples Parthenope
Dr. Meccariello obtained her Degree in Biology at the University of Naples Federico, Italy in 1997. She further got Ph.D. in Comparative Endocrinology at the University of Padova, Italy in 2004. She is presently serving as an Associate Professor of Biology at the Department of Movement and Wellness Sciences at Parthenope University of Naples, Italy. Her field of expertise is in Biology of reproduction, reproductive endocrinology, spermatogenesis, sperm quality, hypothalamus - pituitary - gonad (HPG) axis, endocannabinoids, endocrine disruptor chemicals, central and local regulation of testicular activity in vertebrates. She has contributed more than 80 publications, having citations around 1495.
Marche Polythecnic University
Dr. Roberta Galeazzi got the Chemistry degree in 1992 at the University of Bologna cum laude and worked as researcher since January 1993 at the Polytechnic Marche University where actually she is assistant professor (SSD CHIM/06) of the Department of Life and Environmental Science (DISVA). Dr. Galeazzi’s main research activity concerns molecular docking and molecular dynamics profiling of novel active compounds or natural ligands to their receptors with the aim of rationalize the molecular basis of biological processes fundamental for the transductions of specific biochemical and physiological effects. She is co-author of 80 papers published on international peer-review journals and she attended to many congresses with oral and poster presentations.
Robert Wood Johnson Medical School
Dr. Federico Sesti is a Professor of Neuroscience and Cell Biology, Rutgers University. He received his Laurea and Ph.D. in Physics from the University of Genova, Italy. He was a postdoctoral fellow in the laboratory of Benjamin Kaupp, Institut für Biologische Informationsverarbeitung, Forschungszentrum Jülich (Germany) and in the laboratory of Steve Goldstein at Yale University (USA). He is a Fulbrigh Scholar, and member of several scientific societies. He serves in the editorial board of several journals and in international, federal and private funding agencies.
University of Pisa
Dr. Laura Betti, obtained a PhD in Neurobiology and Clinic of Affective Disorders from the University of Pisa, Italy. In the same University she also received her Speciality in Clinical Biochemistry and her Biological Degree. Currently Dr. Betti is Researcher in Biochemistry at the Department of Pharmacy of the University of Pisa. She has over 20 years of the experience in the research of proteins and their role in transduction mechanisms in physiological and pathological conditions. She has published 100 publications in the fields of biochemistry, as well as clinical biochemistry and neurosciences with particular reference to neurotransmitters and receptor systems.
Universita' degli Studi de Siena
F. Corelli was born in Italy. He graduated in Medicinal Chemistry at University of Rome La Sapienza and joined Artico's group. He served as the Chairman of the University of Siena and was appointed in the Scientific Committee of University of Pisa. He was the director of the Workshop in Synthetic Metodologies of the Italian Chemical Society. He is a member of the Steering Committee of the Italian Chemical Society, EABM of Central Nervous System Agents in Medicinal Chemistry and a reviewer for numerous scientific journals. He is the author of 8 patent applications, 198 scientific papers, 8 book chapters , more than 90 oral/poster communications. He has also been editor of a book.
Johns Hopkins University
Dr. Horti is an Associate Professor in the Department of Radiology and Radiological Science at Johns Hopkins University, Maryland. He has devoted his career to the development of short-lived radiotracers for PET, in particular radioligands for imaging of cerebral receptors and enzymes in human subjects. His scientific results have been published in various peer-reviewed journals, invited reviews supported by NIH, private foundations and pharmaceutical industry. He also holds appointments on editorial boards for several scientific journals. He is an active member of the Society of Nuclear Medicine and Molecular Imaging and he has organized research sessions and continuing education sessions for a number of SNMMI meetings.
University of Arizona
Dr. Hulme received a doctorate degree (D.Phil) in chemistry from the University of Oxford, England. He currently is a full Professor at the University of Arizona and Director of the Medicinal Chemistry BIO5 Drug Discovery Core. Prior to moving to academia, Dr. Hulme built and managed several high-throughput medicinal chemistry organizations in industry (1994 – 2007, Sanofi, Amgen, Lilly), spanning a multitude of therapeutic areas including neurodegeneration through the targeting of CNS kinases. Dr Hulme has > 175 publications, book chapters, and patents.
University Collegium Medicum
Biology and CTO
Dr. Parang is Associate Dean of Research, Graduate Studies and Global Affairs and a Full Professor of Medicinal Chemistry and Pharmacology at Chapman University School of Pharmacy in Irvine, California. He earned a Pharm.D. degree from Tehran University of Medical Sciences in 1989. He received his Ph.D. in medicinal chemistry from the Faculty of Pharmacy at University of Alberta in 1997, followed by a postdoctoral study in the fields of carbohydrate chemistry and solid-phase organic synthesis in Department of Chemistry. He pursued additional postdoctoral studies at Rockefeller University in New York and Johns Hopkins University in Baltimore in bioorganic chemistry. He is an author of 170 peer-reviewed publications, 8 patents, and more than 140 meeting.
Prof. Charles Ramassamy has successively obtained his DEA (Diploma of Advanced Studies) in Molecular and Cellular Pharmacology at Paris V University, and a PhD in Neuroscience, option neuropharmacology, at the University of Rouen in France. After completing a postdoctoral fellowship at McGill University, at the Douglas Mental Health University Institute Research Center in the laboratory of Dr. Judes Poirier, he became professor of pharmacology at the Université du Québec à Trois-Rivières, then professor at the INRS-Institut Armand-Frappier. He is also an associate professor at Laval University and a regular researcher at the Institute on Nutrition and Functional Foods, Laval University.
Vanderbilt University Medical Center
Dr. Shaun Stauffer is currently Assistant Professor in the departments of Pharmacology and Chemistry
at Vanderbilt University and is associate director of medicinal chemistry within the Vanderbilt
Institute for Chemical Biology (VICB) Synthesis Core. Dr. Stauffer received his Ph.D. in 1999 from
the University of Illinois developing combinatorial approaches towards selective estrogen receptor
modulators in the laboratory of Prof. John Katzenellenbogen. Dr. Stauffer then pursued post-doctoral
studies at Yale University as an NIH fellow with Prof. John Hartwig (1999-2001) developing highthroughput
screening platforms for reaction discovery and optimization. From 2001-2008 he pursued an industrial career at Merck & Co.
Associate Editorial Board Member
University of Isfahan
Dr. Maryam Noorbakhshnia is currently an Assistant Professor at the University of Isfahan (Research and teaching different physiology courses to bachelor and master students). She did Ph.D. from Tehran University in 2007 (Major: physiology of the nervous system). Before that, she did her MSc from Tehran University in the year 2000
(Major: physiology of the nervous system).